Swiss Dental Startup vVARDIS Begins Trading on NYSE Under VVVV
vVARDIS, a drill-free cavity treatment company, debuted on the New York Stock Exchange, marking a milestone for the dental biotech sector.
Swiss dental biotech vVARDIS began trading on the New York Stock Exchange under the ticker symbol VVVV on Nov. 13, 2026, marking the company's entry into U.S. public markets. The listing signals growing investor interest in non-invasive dental technologies aimed at addressing widespread oral health challenges.
The company was co-founded by Dr. Haley Abivardi and Dr. Goly Abivardi, who have positioned vVARDIS around a core proposition: treating cavities without a dental drill. Tooth decay is classified by global health organizations as the world's most prevalent non-communicable disease, affecting hundreds of millions of people across income levels and geographies.
Read more M&T Bank Raises Quarterly Dividend 20% to $1.80 Per Share →
vVARDIS's drill-free approach represents a potential shift in how dental care is delivered, targeting a treatment category that has seen little fundamental innovation in decades. The founders argue that eliminating the drill could lower barriers to treatment and reduce patient anxiety, factors that contribute to delayed dental care worldwide.
The NYSE listing provides vVARDIS with access to U.S. capital markets at a moment when health-tech and biotech companies are facing heightened scrutiny from investors demanding clear paths to commercialization and revenue. How the company performs in its early quarters as a public entity will be closely watched by both dental industry observers and biotech investors.
Continue reading at All Financial Services & Investing.